Search results
Cathie Wood Is Buying This Under-the-Radar AI Stock | The Motley Fool
The Motley Fool· 4 days agoMany famous names on Wall Street are rapidly scooping up shares of the most prominent artificial...
US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties
Reuters via AOL· 6 days agoThe latest Biosecure Act also adds WuXi Biologics to a list of biotech companies of concern,...
Uniquity Bio launches to focus on immunology and inflammation
Pharmaceutical Technology via Yahoo Finance· 11 hours ago“Our approach to development pairs the scientific rigour and quality standards of a global pharma ...
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
The Motley Fool via AOL· 4 days agoIn February, the biotech released data from several phase 3 studies for its next-gen CF...terms, the...
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into...
WPRI Providence· 1 day agoEffective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoThe company is working on a drug to treat liver fibrosis due to hepatitis B and metabolic...
Why Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?
InvestorPlace· 1 day agoConsidering the stage of the company’s drug development pipeline, its lack of revenue for the...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via Yahoo Finance· 6 hours agoOn Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical...
Earnings call: Acumen Pharmaceuticals reports progress in ALTITUDE-AD study By Investing.com
Investing.com· 2 days agoAcumen Pharmaceuticals, in its Q1 2024 earnings call, detailed the initiation of the ALTITUDE-AD...
Chinese biotech crackdown would reset U.S. drug development
Axios· 1 day agopharmaceuticals are developed and made, by advancing a contracting ban on five key Chinese research firms. Why it matters: It's...trade and national security concerns have ...